AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
THE EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) COMBINED WITH INTERFERON IN HUMAN RENAL-CELL CARCINOMA CELL-LINES
Authors: ROHDE D HAYN HK BLATTER J JAKSE G
Citation: D. Rohde et al., THE EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) COMBINED WITH INTERFERON IN HUMAN RENAL-CELL CARCINOMA CELL-LINES, International journal of oncology, 12(6), 1998, pp. 1361-1366
THE EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) AND VINBLASTINE COMBINED WITH INTERFERON IN NUDE-MICE XENOGRAFTS OF HUMAN RENAL-CELL CARCINOMA
Authors: ROHDE D GOERTZ M BLATTER J JAKSE G
Citation: D. Rohde et al., THE EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) AND VINBLASTINE COMBINED WITH INTERFERON IN NUDE-MICE XENOGRAFTS OF HUMAN RENAL-CELL CARCINOMA, International journal of oncology, 12(6), 1998, pp. 1367-1372
A MULTICENTER PHASE-II TRIAL OF THE MULTITARGETED ANTIFOLATE MTA (LY231514) IN CHEMONAIVE PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: SAUTER T BOUCSEIN G THOEDTMANN R MILLER K OHNMACHT U BLATTER J HANAUSKE AR
Citation: T. Sauter et al., A MULTICENTER PHASE-II TRIAL OF THE MULTITARGETED ANTIFOLATE MTA (LY231514) IN CHEMONAIVE PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, Annals of oncology, 9, 1998, pp. 291-291
SIGNIFICANTLY HIGHER SURVIVAL WITH GEMCITABINE-CISPLATIN VS CISPLATININ ADVANCED NONSMALL CELL LUNG-CANCER (NSCLC) - FINAL RESULTS FROM ANINTERNATIONAL RANDOMIZED PHASE-III STUDY
Authors: SANDLER A DENHAM C VONPAWEL J CORMIER Y GATZEMEIER U MATTSON K MANEGOLD C GREGOR A BLATTER J EINHORN L
Citation: A. Sandler et al., SIGNIFICANTLY HIGHER SURVIVAL WITH GEMCITABINE-CISPLATIN VS CISPLATININ ADVANCED NONSMALL CELL LUNG-CANCER (NSCLC) - FINAL RESULTS FROM ANINTERNATIONAL RANDOMIZED PHASE-III STUDY, Annals of oncology, 9, 1998, pp. 409-409
PHASE-I STUDY OF DIFFERENT SEQUENCES OF MTA (LY231514) IN COMBINATIONWITH CISPLATIN IN PATIENTS WITH SOLID TUMORS
Authors: THODTMANN R DEPENBROCK H DUMEZ H OHNMACHT U BLATTER J VANOOSTEROM AT HANAUSKE AR
Citation: R. Thodtmann et al., PHASE-I STUDY OF DIFFERENT SEQUENCES OF MTA (LY231514) IN COMBINATIONWITH CISPLATIN IN PATIENTS WITH SOLID TUMORS, Annals of oncology, 9, 1998, pp. 618-618
GEMCITABINE AS SINGLE-AGENT IN THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN-LYMPHOMA (NHL)
Authors: WELT A FOSSA A BLATTER J BUKSMAUI S SEEBER S NOWROUSIAN MR
Citation: A. Welt et al., GEMCITABINE AS SINGLE-AGENT IN THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN-LYMPHOMA (NHL), Annals of oncology, 9, 1998, pp. 643-643
RADIOSENSITIZING POTENTIAL OF GEMCITABINE (2',2'-DIFLUORO-2'-DEOXYCYTIDINE) WITHIN THE CELL-CYCLE IN-VITRO
Authors: LATZ D FLECKENSTEIN K EBLE M BLATTER J WANNENMACHER M WEBER KJ
Citation: D. Latz et al., RADIOSENSITIZING POTENTIAL OF GEMCITABINE (2',2'-DIFLUORO-2'-DEOXYCYTIDINE) WITHIN THE CELL-CYCLE IN-VITRO, International journal of radiation oncology, biology, physics, 41(4), 1998, pp. 875-882
IFOSFAMIDE AND GEMCITABINE - A PHASE-II TRIAL IN ADVANCED INOPERABLE NONSMALL CELL LUNG-CANCER
Authors: GATZEMEIER U MANEGOLD C EBERHARD W WILKE HJ CHOMY F CHOMY P KHAYAT D BLATTER J SEEBER S DRINGS P
Citation: U. Gatzemeier et al., IFOSFAMIDE AND GEMCITABINE - A PHASE-II TRIAL IN ADVANCED INOPERABLE NONSMALL CELL LUNG-CANCER, Seminars in oncology, 25(1), 1998, pp. 15-18
COMBINED EFFECTS OF IONIZING-RADIATION AND GEMCITABINE (GEM) IN DIFFERENT CELL-LINES
Authors: FLECKENSTEIN K LATZ D BLATTER J WEBER KJ
Citation: K. Fleckenstein et al., COMBINED EFFECTS OF IONIZING-RADIATION AND GEMCITABINE (GEM) IN DIFFERENT CELL-LINES, European journal of cancer, 33, 1997, pp. 105-105
RADIATION ENHANCEMENT OF GEMCITABINE(R) IN 3 HUMAN CERVICAL-CANCER CELL-LINES
Authors: WALLWIENER D KUREK R ANGIOLI R JANICEK M PENALVER M BLATTER J EBLE E DIEL IJ BASTERT G SEVIN BU
Citation: D. Wallwiener et al., RADIATION ENHANCEMENT OF GEMCITABINE(R) IN 3 HUMAN CERVICAL-CANCER CELL-LINES, European journal of cancer, 33, 1997, pp. 923-923
GEMCITABINE AND ETOPOSIDE IN CHEMONAIVE PATIENTS WITH EXTENSIVE SMALL-CELL LUNG-CANCER (SCLC) - PRELIMINARY PHASE-II RESULTS
Authors: VONPAWEL J GATZEMEIER U VANSTEENKISTE J WEYNANTS P HANAUSKE A BOSQUEE L MANSOURI K ZNAMENSKY S BLATTER J MANEGOLD C
Citation: J. Vonpawel et al., GEMCITABINE AND ETOPOSIDE IN CHEMONAIVE PATIENTS WITH EXTENSIVE SMALL-CELL LUNG-CANCER (SCLC) - PRELIMINARY PHASE-II RESULTS, European journal of cancer, 33, 1997, pp. 1054-1054
A PHASE-I STUDY OF MTA (MULTITARGETED ANTIFOLATE, LY231514) PLUS CISPLATIN (CIS) IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: THOEDTMANN R KEMMERICH M DEPENBROCK H BLATTER J OHNMACHT U RASTETTER J HANAUSKE AR
Citation: R. Thoedtmann et al., A PHASE-I STUDY OF MTA (MULTITARGETED ANTIFOLATE, LY231514) PLUS CISPLATIN (CIS) IN PATIENTS WITH ADVANCED SOLID TUMORS, European journal of cancer, 33, 1997, pp. 1116-1116
ACTIVITY AND TOLERABILITY OF GEMCITABINE PLUS CISPLATIN IN ADVANCED METASTATIC PANCREATIC-CARCINOMA
Authors: HEINEMANN V WILKE H POSSINGER K MERGENTHALER K CLEMENS M KONIG HJ ILLIGER HJ LACKHOFF A BLATTER J SCHALLHORN A FINK U
Citation: V. Heinemann et al., ACTIVITY AND TOLERABILITY OF GEMCITABINE PLUS CISPLATIN IN ADVANCED METASTATIC PANCREATIC-CARCINOMA, European journal of cancer, 33, 1997, pp. 1240-1240
GEMCITABINE IN SOLID TUMORS - PRESENT STATUS AND FURTHER DEVELOPMENT
Authors: ARNING M BLATTER J
Citation: M. Arning et J. Blatter, GEMCITABINE IN SOLID TUMORS - PRESENT STATUS AND FURTHER DEVELOPMENT, Onkologie, 20(4), 1997, pp. 297-304
PET 2-FLUORO-2-DEOXYGLUCOSE UPTAKE IN RAT PROSTATE ADENOCARCINOMA DURING CHEMOTHERAPY WITH GEMCITABINE
Authors: HABERKORN U BELLEMANN ME ALTMANN A GERLACH L MORR I OBERDORFER F BRIX G DOLL J BLATTER J VANKAICK G
Citation: U. Haberkorn et al., PET 2-FLUORO-2-DEOXYGLUCOSE UPTAKE IN RAT PROSTATE ADENOCARCINOMA DURING CHEMOTHERAPY WITH GEMCITABINE, The Journal of nuclear medicine, 38(8), 1997, pp. 1215-1221
A PHASE-II TRIAL OF GEMCITABINE AND IFOSFAMIDE IN NONSMALL CELL LUNG-CANCER
Authors: GATZEMEIER U MANEGOLD C EBERHARD W WILKE HJ CHOMY F CHOMY P KHAYAT D BLATTER J SEEBER S DRINGS P
Citation: U. Gatzemeier et al., A PHASE-II TRIAL OF GEMCITABINE AND IFOSFAMIDE IN NONSMALL CELL LUNG-CANCER, Seminars in oncology, 24(3), 1997, pp. 836-838
GEMCITABINE AND ETOPOSIDE IN SMALL-CELL LUNG-CANCER - PHASE-I AND PHASE-II TRIALS
Authors: RASSMANN I THODTMANN R DEPENBROCK H BLATTER J GATZEMEIER U RASTETTER J HANAUSKE AR
Citation: I. Rassmann et al., GEMCITABINE AND ETOPOSIDE IN SMALL-CELL LUNG-CANCER - PHASE-I AND PHASE-II TRIALS, Seminars in oncology, 24(2), 1997, pp. 75-78
GEMCITABINE - A PHASE-II STUDY IN PATIENTS WITH ADVANCED RENAL-CANCER
Authors: DEMULDER PHM WEISSBACH L JAKSE G OSIEKA R BLATTER J
Citation: Phm. Demulder et al., GEMCITABINE - A PHASE-II STUDY IN PATIENTS WITH ADVANCED RENAL-CANCER, Cancer chemotherapy and pharmacology, 37(5), 1996, pp. 491-495
METABOLIC EFFECTS OF GEMCITABINE IN RAT PROSTATE ADENOCARCINOMAS
Authors: HABERKORN U BELLEMANN ME OBERDORFER F MORR I GERLACH L BLATTER J TROJAN H DOLL J VANKAICK G
Citation: U. Haberkorn et al., METABOLIC EFFECTS OF GEMCITABINE IN RAT PROSTATE ADENOCARCINOMAS, The Journal of nuclear medicine, 37(5), 1996, pp. 1188-1188
EXPERIMENTAL AND CLINICAL EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) AGAINST RENAL-CELL CARCINOMA
Authors: ROHDE D DEMULDER PHM WEISSBACH L OSIEKA R BLATTER J JAKSE G
Citation: D. Rohde et al., EXPERIMENTAL AND CLINICAL EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) AGAINST RENAL-CELL CARCINOMA, Oncology, 53(6), 1996, pp. 476-481
PHASE-II STUDY OF GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC-CANCER
Authors: CARMICHAEL J FINK U RUSSELL RCG SPITTLE MF HARRIS AL SPIESSI G BLATTER J
Citation: J. Carmichael et al., PHASE-II STUDY OF GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC-CANCER, British Journal of Cancer, 73(1), 1996, pp. 101-105
ADVANCED BREAST-CANCER - A PHASE-II TRIAL WITH GEMCITABINE (GEM)
Authors: POSSINGER K KAUFMANN M HELSING M COLEMAN R BLATTER J
Citation: K. Possinger et al., ADVANCED BREAST-CANCER - A PHASE-II TRIAL WITH GEMCITABINE (GEM), European journal of cancer, 31A, 1995, pp. 369-369
GEMCITABINE - CLINICAL AND ECONOMIC-IMPACT IN INOPERABLE NON-SMALL-CELL LUNG-CANCER
Authors: KOCH P JOHNSON N VANSCHAIK J ANDERSEN S BLATTER J BOSANQUET N COPLEYMERRIMAN K DRINGS P
Citation: P. Koch et al., GEMCITABINE - CLINICAL AND ECONOMIC-IMPACT IN INOPERABLE NON-SMALL-CELL LUNG-CANCER, Anti-cancer drugs, 6, 1995, pp. 49-54
SERUM-ALBUMIN (SA) ACCUMULATION BY BRONCHOGENIC TUMORS - A TRACER TECHNIQUE MAY HELP WITH PATIENT SELECTION FOR SA-DELIVERED CHEMOTHERAPY
Authors: CLORIUS JH SINN H MANKE HG SCHRENK HH BLATTER J WERLING C FRIEDRICH EA VOGES J BAHNER M STURM V DRINGS P VANKAICK G
Citation: Jh. Clorius et al., SERUM-ALBUMIN (SA) ACCUMULATION BY BRONCHOGENIC TUMORS - A TRACER TECHNIQUE MAY HELP WITH PATIENT SELECTION FOR SA-DELIVERED CHEMOTHERAPY, European journal of nuclear medicine, 22(9), 1995, pp. 989-996
CHANGES IN FDG UPTAKE AFTER CHEMOTHERAPY WITH GEMCITABINE IN PROSTATECARCINOMA-CELLS
Authors: HABERKORN U OBERDORFER F BELLEMANN ME BLATTER J MORR I BRIX G
Citation: U. Haberkorn et al., CHANGES IN FDG UPTAKE AFTER CHEMOTHERAPY WITH GEMCITABINE IN PROSTATECARCINOMA-CELLS, Radiology, 197, 1995, pp. 421-421
Risultati: 1-25 | 26-27